PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-37.13%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
225.85%
Gross profit growth above 1.5x ECL.AX's 8.35%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-24.46%
Negative EBIT growth while ECL.AX is at 6.76%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.46%
Negative operating income growth while ECL.AX is at 6.76%. Joel Greenblatt would press for urgent turnaround measures.
-40.11%
Negative net income growth while ECL.AX stands at 6.05%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-50.00%
Negative EPS growth while ECL.AX is at 6.04%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-33.33%
Negative diluted EPS growth while ECL.AX is at 6.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
8.39%
Slight or no buybacks while ECL.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-8.85%
Reduced diluted shares while ECL.AX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-93.22%
Negative OCF growth while ECL.AX is at 43690.91%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-96.76%
Negative FCF growth while ECL.AX is at 9531.37%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-36.39%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
36.85%
5Y revenue/share CAGR under 50% of ECL.AX's 126.34%. Michael Burry would suspect a significant competitive gap or product weakness.
45.47%
3Y revenue/share CAGR similar to ECL.AX's 44.87%. Walter Schloss would assume both companies experience comparable short-term cycles.
646.76%
10Y OCF/share CAGR above 1.5x ECL.AX's 44.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
99.23%
Below 50% of ECL.AX's 1024.38%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
281.81%
3Y OCF/share CAGR under 50% of ECL.AX's 1926.74%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
124.64%
Positive 10Y CAGR while ECL.AX is negative. John Neff might see a substantial advantage in bottom-line trajectory.
-20.00%
Negative 5Y net income/share CAGR while ECL.AX is 154.40%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
100.00%
3Y net income/share CAGR above 1.5x ECL.AX's 54.60%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
190.38%
5Y equity/share CAGR above 1.5x ECL.AX's 32.70%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
33.42%
3Y equity/share CAGR 1.25-1.5x ECL.AX's 28.97%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
165.11%
AR growth well above ECL.AX's 3.78%. Michael Burry fears inflated revenue or higher default risk in the near future.
-16.74%
Inventory is declining while ECL.AX stands at 17.85%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-14.48%
Negative asset growth while ECL.AX invests at 12.21%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-15.79%
We have a declining book value while ECL.AX shows 4.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-5.14%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-100.00%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
1578.79%
SG&A growth well above ECL.AX's 6.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.